IBM, Accelrys join hands to boost drug development

By Sumner Lemon
Wednesday, 20 February, 2002


IBM and software developer Accelrys have announced an alliance aimed at developing collaborative applications that will help pharmaceutical companies shorten the development cycles for new drugs.

The partnership with IBM will help Accelrys speed the release of its Discovery Studio platform, the companies said. No release date was given for Discovery Studio.

Discovery Studio is designed to shorten the drug development cycle by allowing researchers to capture and re-use scientific data that is generated by a range of sources, including Accelrys life sciences applications as well as software products developed by third parties. To help make this possible, Accelrys will incorporate support for IBM's DiscoveryLink data integration technology in Discovery Studio, the companies said.

Under terms of the four-year alliance, announced on Monday, Accelrys will use a range of high-end servers from IBM for software development, testing and knowledge management applications. As part of the alliance, IBM and Accelrys will also offer joint consulting and implementation services to deploy systems based on products from the two companies.

Related News

Remdesivir approved by TGA to treat COVID-19

Remdesivir has been described as the most promising treatment option so far to reduce...

Age-related impairments could be reversed

Two impairments of old age — frailty and immunity decline — can be halted and even...

Ultrasound-activated microbubbles destroy cancer cells

A non-invasive technology platform utilises low-frequency ultrasound (250 kHz) to detonate...


  • All content Copyright © 2020 Westwick-Farrow Pty Ltd